Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with investments in three European biotechs. Sanifit led the way, raising a €55.2 million ($62.9 million) series D ...
HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim ...
Halozyme, a biotech firm whose drug delivery technology is a key component of biologic medicines marketed by several big pharma partners, aims to expand its offerings to these customers through the ...
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim ...
Halozyme has withdrawn its offer to buy biopharmaceutical services firm Evotec for €2 billion, a move that comes after repeated requests to meet with the company to discuss a deal were all turned down ...
Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, ...
Germany-based CRO Evotec is buying U.S. counterpart Aptuit in a $300 million deal, broadening expertise in the respiratory and fibrosis therapeutic areas, while filling the service gap between ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback